In this article, we will look at some of the best penny stocks in the life sciences sector that currently offer attractive upside potential for investors.
On March 11, CBRE shared an analysis covering the U.S. market trends in life sciences real estate. The analysis reviewed the factors behind the recovery process in the life sciences real estate, which had been suffering from oversupply, risk aversion, and inactivity in the capital markets for two years. The analysis should not be ignored by investors who follow this market segment.
The major takeaway was that construction activity is expected to hit its 10-year low point, characterized by lower lab and R&D construction. This would eventually reduce pressure across the U.S. life sciences segment, and most importantly, would lead to improved fundamentals. Several positive trends were noted by CBRE at the end of 2025, with even greater improvement expected in 2026, indicating a change in the business cycle. The firm also pointed out some positive developments in both the stock market and venture capital investments, which typically precede an increase in the demand for laboratories, before entering 2026.
Investments in laboratory facilities have never been higher, underscoring the country’s reputation as a leader in life sciences worldwide. Investors, according to CBRE, can expect irregular demand trends because of the historically high patent cliff, fast-tracked drug approvals, diversified funding sources, and China’s growing importance in global R&D.
With that background, let’s explore our 8 Best Life Sciences Penny Stocks to Buy.
Tonhom1009/Shutterstock.com
Our Methodology
To identify relevant stocks for this article, we conducted a screening of U.S.-listed life sciences penny stocks with market capitalizations above $200 million. Also, we only shortlisted names with at least 20% upside potential according to analyst consensus, as of April 8 closing. Finally, we selected 8 stocks with the highest upside and ranked them in ascending order.
Why are we interested in the stocks that hedge funds pile into? The reason is simple: our research has shown that we can outperform the market by imitating the top stock picks of the best hedge funds. Our quarterly newsletter’s strategy selects 14 small-cap and large-cap stocks every quarter and has returned 498.7% since May 2014, beating its benchmark by 303 percentage points (see more details here).
8. Nautilus Biotechnology Inc. (NASDAQ:NAUT)
Nautilus Biotechnology Inc. (NASDAQ:NAUT) is one of the 8 Best Life Sciences Penny Stocks to Buy.
On March 18, Nautilus Biotechnology Inc. (NASDAQ:NAUT) announced Baylor College of Medicine as the first customer of Nautilus’s Iterative Mapping Early Access Program. Baylor will be utilizing the Nautilus single-molecule proteomics technology through a National Institutes of Health U01 grant, which will allow Baylor to address one of the fundamental problems in cancer biology research. This involves understanding the roles of altered protein isoforms in promoting tumor growth, metastasis, immune escape, and drug resistance.
As Nautilus increases its commercial availability by using its validated tau proteoforms assay, Baylor will focus on creating innovative methods for detecting proteins. In the research study, Baylor will focus on creating a user-friendly computational tool kit with better detection capabilities of protein isoforms from traditional shotgun proteomics data sets.
Through the combination of computational techniques with high-resolution, full-length protein isoform profiling data sets generated using the Nautilus Voyager platform, this research project is expected to allow researchers to directly compare changes between transcriptional and proteomic events at an unprecedented level of detail.
Nautilus Biotechnology Inc. (NASDAQ:NAUT) is involved in the development of a technological platform for quantifying and unlocking the complexity of the proteome. Its platform offers end-to-end solutions involving reagents, consumables, and more. Its portfolio also includes optical imaging systems, single-molecule library kits, affinity reagents, and flow cells.
